Halozyme Therapeutics, Inc. | |||||||
Condensed Consolidated Balance Sheets | |||||||
June 30, | December 31, | ||||||
2010 | 2009 | ||||||
(unaudited) | |||||||
ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ 41,312,426 | $ 67,464,506 | |||||
| Accounts receivable | 2,253,771 | 4,243,909 | |||||
| Inventory | 1,081,876 | 1,159,551 | |||||
| Prepaid expenses and other assets | 4,676,229 | 1,573,777 | |||||
| Total current assets | 49,324,302 | 74,441,743 | |||||
| Property and equipment, net | 2,161,549 | 2,708,016 | |||||
| Total Assets | $ 51,485,851 | $ 77,149,759 | |||||
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ 2,101,349 | $ 2,820,491 | |||||
| Accrued expenses | 4,134,661 | 6,083,854 | |||||
| Deferred revenue | 4,825,735 | 5,492,604 | |||||
| Total current liabilities | 11,061,745 | 14,396,949 | |||||
| Deferred revenue, net of current portion | 53,857,056 | 54,989,588 | |||||
| Deferred rent, net of current portion | 684,315 | 859,833 | |||||
| Stockholders' (deficit) equity: | |||||||
| Common stock | 92,010 | 91,682 | |||||
| Additional paid-in capital | 181,739,270 | 178,821,852 | |||||
| Accumulated deficit | (195,948,545) | (172,010,145) | |||||
| Total stockholders' (deficit) equity | (14,117,265) | 6,903,389 | |||||
| Total Liabilities and Stockholders' (Deficit) Equity | $ 51,485,851 | $ 77,149,759 | |||||
